BACKGROUND: Activated V gamma 9 V delta 2 T cells are able to kill mosttumour cells because of recognition by T cell receptor and natural killerreceptors.OBJECTIVE: We discuss the possibility that the intentional activation ofgammadelta T cells in vivo by aminobisphosphonates may represent a promisingtarget for the design of novel and highly innovative immunotherapy in cancerpatients.METHODS: The antitumoral effects of gammadelta T cells both in vitro and invivo have been demonstrated suggesting a new therapeutic approach fortranslation into the clinical setting.RESULTS/CONCLUSION: V gamma 9 V delta 2 T lymphocytes represent aparticularly interesting target for immunotherapeutic protocols based on N-aminobisphosphonate administration and several Phase I-II trials are ongoinginvestigating the activity of zoledronic acid plus IL-2 in solid tumours.
|Number of pages||9|
|Journal||Expert Opinion on Biological Therapy|
|Publication status||Published - 2008|
All Science Journal Classification (ASJC) codes
- Drug Discovery
- Clinical Biochemistry